Durable Responses to Afatinib as First-line Therapy for HER2-mutated Metastatic Non-small-cell Lung Cancer

Clin Lung Cancer. 2020 Jan;21(1):e15-e20. doi: 10.1016/j.cllc.2019.09.006. Epub 2019 Sep 26.

Authors

Ebaa Al-Obeidi¹, Tianhong Li², Karen Kelly³

Affiliations

¹ Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, CA.
² University of California Davis Comprehensive Cancer Center, Sacramento, CA.
³ University of California Davis Comprehensive Cancer Center, Sacramento, CA. Electronic address: karkelly@ucdavis.edu.

PMID: 31649001
DOI: 10.1016/j.cllc.2019.09.006

No abstract available

Keywords: Lung adenocarcinoma; Never smoking women; Oncogenic driven tumor; Tyrosine kinase inhibitor; Untreated metastatic disease.

Publication types

Case Reports

MeSH terms

Afatinib / administration & dosage*
Aged
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics
Carcinoma, Non-Small-Cell Lung / secondary
Female
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Lung Neoplasms / pathology
Male
Molecular Targeted Therapy / methods*
Protein Kinase Inhibitors / administration & dosage
Receptor, ErbB-2 / genetics*
Treatment Outcome

Substances

Protein Kinase Inhibitors
Afatinib
ERBB2 protein, human
Receptor, ErbB-2